| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Celldex Therapeutics Inc (NASDAQ: CLDX)
CLDX Technical Analysis
3
| As on 9th Jun 2023 CLDX SHARE Price closed @ 34.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 31.33 & Buy for SHORT-TERM with Stoploss of 32.81 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CLDXSHARE Price
| Open | 35.74 | Change | Price | % |
| High | 36.02 | 1 Day | -0.77 | -2.16 |
| Low | 34.53 | 1 Week | 3.00 | 9.43 |
| Close | 34.80 | 1 Month | 3.07 | 9.68 |
| Volume | 501500 | 1 Year | -4.55 | -11.56 |
| 52 Week High 47.43 | 52 Week Low 20.50 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CLDX Daily Charts |
CLDX Intraday Charts |
Whats New @ Bazaartrend |
CLDX Free Analysis |
|
|
CLDX Important Levels Intraday
| RESISTANCE | 37.67 |
| RESISTANCE | 36.75 |
| RESISTANCE | 36.18 |
| RESISTANCE | 35.61 |
| SUPPORT | 33.99 |
| SUPPORT | 33.42 |
| SUPPORT | 32.85 |
| SUPPORT | 31.93 |
CLDX Forecast April 2024
| 4th UP Forecast | 55.77 |
| 3rd UP Forecast | 49.04 |
| 2nd UP Forecast | 44.89 |
| 1st UP Forecast | 40.73 |
| 1st DOWN Forecast | 28.87 |
| 2nd DOWN Forecast | 24.71 |
| 3rd DOWN Forecast | 20.56 |
| 4th DOWN Forecast | 13.83 |
CLDX Weekly Forecast
| 4th UP Forecast | 43.84 |
| 3rd UP Forecast | 40.94 |
| 2nd UP Forecast | 39.15 |
| 1st UP Forecast | 37.36 |
| 1st DOWN Forecast | 32.24 |
| 2nd DOWN Forecast | 30.45 |
| 3rd DOWN Forecast | 28.66 |
| 4th DOWN Forecast | 25.76 |
CLDX Forecast2024
| 4th UP Forecast | 89.82 |
| 3rd UP Forecast | 72.17 |
| 2nd UP Forecast | 61.27 |
| 1st UP Forecast | 50.36 |
| 1st DOWN Forecast | 19.24 |
| 2nd DOWN Forecast | 8.33 |
| 3rd DOWN Forecast | -2.57 |
| 4th DOWN Forecast | -20.22 |
Celldex Therapeutics Inc ( NASDAQ USA Symbol : CLDX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CLDX Business Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Address: Perryville III Building, Hampton, NJ, United States, 08827
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service